P/B
0,6
Tenax Therapeutics
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
$70M
Market Cap • 10/9/2026
1967
(59 years)
Founded
1995
(31 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
3
EPS
1,5
Market Cap
Market Cap
70M
EV
-48M
EV/Revenue
0
EV/EBITDA
0,7
EV/EBIT
0,7
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-83,7%
Total Yield
-83,7%
Payout
0%
Retained Earnings
-401M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0%
% Goodwill
0%
ROE
59,8%
ROIC
—
Growth
CAGR Op. Income 5Y
17,4%
CAGR EPS 5Y
-76,2%
CAGR OCF 5Y
37,3%
Leverage
N.D./EBITDA
1,7
Debt/Equity
0%
Current Ratio
15,1
Quick Ratio
14,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!